Related Experiment Video

Updated: Nov 1, 2025

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.7K

Melanoma Engages Genetic and Nongenetic Drug Resistance Trajectories

    Cancer Discovery
    |June 26, 2021
    PubMed

    Insights

    Melanoma cells develop resistance to MAPK inhibitors through genetic mutations and non-genetic adaptive strategies. Understanding these resistance mechanisms is crucial for improving melanoma treatment outcomes.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Research

    Background:

    • Melanoma is a significant skin cancer with increasing incidence.
    • MAPK pathway inhibitors are a cornerstone of melanoma treatment.
    • Acquired resistance limits the long-term efficacy of these targeted therapies.

    Purpose of the Study:

    • To elucidate the diverse mechanisms by which melanoma cells acquire resistance to MAPK inhibitors.
    • To differentiate between genetic and non-genetic resistance pathways.

    Main Methods:

    • Analysis of patient-derived melanoma cell lines and xenografts.
    • Genomic profiling to identify mutations.
    • Functional assays to assess cellular adaptation and signaling pathway alterations.

    Main Results:

    • Identified specific genetic mutations conferring resistance.
    • Characterized non-genetic adaptive mechanisms, including epigenetic modifications and signaling rewiring.
    • Demonstrated that both genetic and non-genetic factors contribute to treatment failure.

    Conclusions:

    • Melanoma resistance to MAPK inhibitors is multifactorial, involving both genetic alterations and adaptive non-genetic strategies.
    • Targeting both genetic and non-genetic resistance mechanisms may overcome treatment limitations.
    • Further research is needed to develop combination therapies for durable responses.

    More Related Videos

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

    Published on: March 8, 2022

    2.6K
    A 3D Organotypic Melanoma Spheroid Skin Model08:49

    A 3D Organotypic Melanoma Spheroid Skin Model

    Published on: May 18, 2018

    16.1K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.5K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.3K
    Skin Cancer01:30

    Skin Cancer

    Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
    Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
    5.0K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.0K
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
    6.1K
    Cancer02:18

    Cancer

    Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
    51.3K